je.st
news
Home
› Agenus Vaccine Shows Significant Reduction in Viral Burden after HerpV Generated Immune Activation
Agenus Vaccine Shows Significant Reduction in Viral Burden after HerpV Generated Immune Activation
2014-06-26 18:42:26| Biotech - Topix.net
Agenus Inc. , an immuno-oncology company developing a portfolio of checkpoint modulators , heat shock protein peptide-based vaccines, and adjuvants, today announced promising Phase 2 results for HerpV, a synthetic vaccine candidate for the treatment of patients with genital Herpes Simplex Virus-2 .
Tags: shows
significant
generated
reduction
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||